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ACKGROUND: Neopterin is a soluble 
biomarker of monocyte activation and its 
increased concentration might be expressed in 
atherosclerosis. Until recently, there has been lacking 
of information on the prognostic role of neopterin 
in acute coronary syndromes (ACS). The study was 
aimed at measuring the associations between elevated 
serum neopterin and increased risk of cardiovascular 
(CV) events in ACS.
METHODS AND RESULTS: This was a prospective 
cohort study, recruited 71 ACS patients from January 
31 through August 31, 2007 in Sanglah Hospital 
of Udayana School of Medicine, Denpasar – Bali. 
Cardiovascular events, such as: CV death, recurrent 
myocardial infarction, stroke and recurrent myocardial 
ischemia were previously deﬁned. Relative risk and 
survival rate were measured successively by Cox 
proportional model and Kaplan-Meier curve. 
Of 71 ACS patients aged 56.8 ± 9.5 years, 21 (29.5%) 
subjects underwent CV events. Overall mean follow-
up was 151.6 (95% CI: 129.7 – 173.5) days. Baseline 
characteristic were similarly distributed between 
groups with the highest quartile neopterin level (≥ 14.7 
nmol/L) than those with lowest quartile (≤ 6.2 nmol/
L). Patients with the highest quartile had the worst 
survival curve than those with the lowest quartile 
(log-rank test; P = 0.047). On Cox proportional model, 
relative risk of highest quartile group was 5.84 (95% 
CI: 1.19 – 28.47; P = 0.029) compared to lowest quartile, 
after being adjusted with other predictors.
CONCLUSIONS: Elevated serum neopterin is 
associated with increased risk of CV events in acute 
coronary syndromes.
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Inﬂammation plays an important role in atherosclerosis 
and plaque vulnerability (1). Activated macrophages 
contribute to both atherosclerotic plaque disruption 
and intracoronary thrombus formation, often leading 
to acute coronary syndromes (ACS). Plaque disruption 
usually takes place at the thinnest ﬁbrous cap and is 
mostly inﬁltrated with macrophages (2). The activated 
macrophages produce inﬂammatory cytokines, 
protease, and cytotoxic oxygen and nitrogen radical 
molecules (3). Macrophages activated by interferon-  
(IFN- ) also synthesize neopterin (4).
Neopterin, a pteridine derivative and a by-
product of the guanosine triphosphate-biopterin 
pathway and produced by activated monocyte 
(5,6) is thought to represent a marker of immune 
activation and macrophage activity (4). It is elevated 
in a number of autoimmune and infectious disease 
states (6). Because of its relative stability and ease of 
assay has made it a subject for research as a mean 
to monitor disease activity. Acute inﬂammatory 
markers such as high neutrophil count, hs-CRP, and 
neopterin concentration correlate with the presence of 
multiple angiographically complex coronary stenoses. 
Neopterin concentration was considered as a stronger 
predictor of multiple complex plaques than were 
neutrophil count and hs-CRP (7).      
A previous study has shown that serum neopterin 
is an independent predictor of major adverse coronary 
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events in those with chronic stable angina pectoris (8). 
It is also elevated in patients with ACS compared to 
those with stable ischemic heart disease (9). Likewise, 
high serum neopterin levels predict the development 
of acute coronary events in women with chronic stable 
angina pectoris (10) and hypertensive patients without 
signiﬁcant obstructive coronary artery disease (CAD) 
(11). Until recently, unfortunately, there has been lack 
of scientiﬁc information on the prognostic value of 
neopterin in ACS in non-Caucasian population. Only 
one study reported elevated plasma neopterin level, 
which might identify patients at long-term risk of 
death or recurrent acute coronary events after ACS in 
Caucasian (12). 
In the present study we prospectively measured 
the associations between elevated serum neopterin 
and increased risk of cardiovascular (CV) events in 
ACS in Bali. Speciﬁcally, we assessed the relative risk 
of elevated serum neopterin in association with CV 
events and survival rate of patients with ACS.
Patients & Methods
PATIENTS AND STUDY PROTOCOLS
This was a prospective cohort study carried out from 
January 31 to August 31, 2007, involving 77 ACS 
patients admitted to Sanglah Hospital of Udayana 
University School of Medicine, Denpasar – Bali. Patients 
with ACS (aged 30 – 74 years) were consecutively 
recruited in the study, who had agreed to participate 
by signing the written informed consent. The local 
ethics committee of our hospital approved the study. 
This is a top referral Public Hospital (teaching hospital 
as well) for Bali Island and its surrounding smaller 
islands.  
Exclusion criteria included ACS subjects with 
rheumatic heart disease, acute and chronic liver disease, 
chronic kidney disease (represented by creatinin 
clearance using Cockroft Gault formula ≤ 60 ml/1.73 
m2/min), infectious disease, and malignancy. 
DEFINITIONS OF CARDIOVASCULAR RISK
FACTORS 
Hypertension was diagnosed in the presence of 
a systolic blood pressure of ≥ 140 mmHg and/or 
diastolic blood pressure of ≥ 90 mmHg as measured 
on at least two separate occasions. Patients receiving 
antihypertensive medications were also regarded 
to suffer hypertension, irrespective of the blood 
pressure recordings at study entry (13). Patients were 
considered to have diabetes mellitus if they were taking 
active treatment with insulin or oral hypoglycemic 
agents, or the fasting blood glucose ≥ 126 mg/dL 
and/or random blood glucose ≥ 200 mg/dL (14). 
Hypercholesterolemia was deﬁned as a documented 
total cholesterol concentration > 200 mg/dL. Smoking 
status was deﬁned as: a) non-smoker for those who 
never had smoked, b) ex-smoker, for those who ever 
had smoked but already had quit at study entry, c) 
current smoker, those which was active smoker at 
study entry (15). Obesity was diagnosed by measuring 
body mass index.      
BIOCHEMICAL MEASUREMENTS
Venous blood was collected from all subjects at the 
time of admission for routine laboratory examination. 
Serum neopterin concentration was taken at 3rd 
hospitalization day, and measured using a commercially 
available immunoassay kit (ELISA Kit, IBL, Hamburg, 
Germany) by a qualiﬁed laboratory technician 
blinded to clinical characteristics and CV events. The 
within-coefﬁcient variability was 3.6 – 6.8% in the 7.7 
– 48 nmol/L range; it has very good correlation with 
HPLC (high performance liquid chromatography) 
measurement (r = 0.97). Limit of detection reached as 
low as 0.7 nmol/L (16). Neopterin concentrations were 
divided into quartile ranges with regard to planned 
analysis, as shown by previous study (12).    
CLINICAL CHARACTERIZATION, FOLLOW-UP, 
AND CLINICAL OUTCOMES
Data acquired at study entry included age, gender, 
height, weight, blood pressure, risk factors history 
including diabetes mellitus, hypertension, and 
family history of CAD, smoking, dyslipidemia. Killip 
classiﬁcation and the Canadian Cardiovascular Society 
(CCS) functional class, as well as cardiac medications 
were recorded at study entry.  
After recruitment, routine baseline characterization 
was carried out in all subjects, who were then followed 
for up to 7 months of study period. All subjects, after 
discharged from the hospital were encouraged to visit 
the outpatient clinic unit of Sanglah Hospital. Subjects 
who did not regularly visit the hospital were further 
followed up by performing home visit. This effort was 
made to avoid loss-to follow-up. At the end of study, a 
total of 71 ACS subjects remained in the analysis, and 
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6 subjects had refused to participate. 
The cardiovascular events determined as pre-
speciﬁed clinical outcomes for this analysis included 
CV mortality, recurrent myocardial infarction, stroke 
and recurrent myocardial ischemia. These clinical 
outcomes were assessed by research assistants.  
STATISTICAL ANALYSIS
Prior to beginning of the study, we calculated the 
number of the patients needed to have a power of 80% 
with predicted relative risk of 3.7 at the 0.05 level of 
signiﬁcance. The estimated minimal sample size was 
70.      
Normally distributed continuous variables were 
expressed as the mean ± standard deviation (SD), and 
continuous variables with non-normal distribution 
were presented as median values (interquartile range). 
Analysis of normality of the continuous variables 
PARTICIPANTS 
Initially 77 subjects with ACS were recruited in the 
study, of which approximately 40% had an index 
diagnosis of ST-elevation myocardial infarction (MI), 
13% had a diagnosis of non-ST elevation MI and 
the rest had unstable angina. Eventually, 71 subjects 
remained in the analysis and 6 subjects refused to 
participate without any reason. No loss to follow-up 
was noted in this study.        
Neopterin concentrations were divided into 
quartile ranges. Elevated serum neopterin group 
was those subjects with neopterin concentration ≥ 
14.72 nmol/L. Along 213 median-days of follow-up, 
21 (28.2%) subjects underwent CV events. Baseline 
clinical characteristics, biochemical and treatment 
pattern results are shown in Table 1. All the clinical 
characteristics, biochemical and treatment pattern are 
identical between groups.  
CLINICAL OUTCOMES 
The cardiovascular events determined as pre-
speciﬁed clinical outcomes for this analysis included 
CV mortality, recurrent MI, stroke and recurrent 
myocardial ischemia, as presented in Table 2. Along 213 
median-days of follow-up, 28.2% subjects underwent 
CV events, namely: 4 (19.0%) subjects had CV deaths, 
2 (9.5%) had recurrent MI and 15 (71.5%) subjects 
suffered recurrent myocardial ischemia. 
KAPLAN-MEIER SURVIVAL CURVE
Kaplan-Meier survival curve shows that the highest 
quartile group of neopterin had survival curve 
signiﬁcantly worse than those in the lowest quartile 
group (log-rank test; P = 0.047), as presented in Figure 
1. The highest quartile group had the mean survival 
shorter compared to the lowest quartile group {69.7 
(95% CI: 48.1 – 91.2 days) vs. 190.5 (95% CI: 161.1 – 
219.8); P = 0.047 days}. 
RISK OF CARDIOVASCULAR EVENTS 
After multivariable adjustment, the relative risk of 
CV events is signiﬁcantly associated with a serum 
neopterin concentration of ≥ 14.72 nmol/L (RR, 
5.84 [95% CI: 1.19 to 28.47]; P = 0.029). Before being 
adjusted with other predictors, the RR was 6.63 (95% 
CI: 1.37 to 32); P = 0.018. The other predictors being 
considered as important risk factors were age, history 
of hypertension, diabetes mellitus, and family history 
of CAD.   
Results
was performed with the Kolmogorov-Smirnov test. 
Homogeneity of variance was also tested using the 
Leven’s test.
In order to have true association between elevated 
serum neopterin and clinical outcomes of interest, we 
constructed a Cox proportional model that adjusted 
for age, history of diabetes mellitus, hypertension, 
and family history of CAD to assess relative risk 
over 7 months. Relative risk was expressed with 95% 
conﬁdence interval. Survival rate was also determined 
using Kaplan-Meier survival curve. Differences were 
considered to be statistically signiﬁcant if the null 
hypothesis would be rejected with > 95% conﬁdence. 
The SPSS 13.0 statistical software package was used 
for calculations.
The authors had full access to the data and take 
full responsibility for its integrity. All authors have 
read and agree to the manuscript as written.  
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Table 1. Baseline characteristics of 71 consecutive subjects with ACS
    
     Low neopterin group*  High neopterin group†
Age, (year)    56.4 ± 9.9   58.0 ± 8.2
Male gender, (%)    71.7    77.8
Blood pressure, mmHg
 S ystolic    120.2 ± 17.7   1 15.1 ± 13.3
 D iastolic    72.3 ± 12.5   72.2 ± 12.4
Body mass index, kg/m2    24.9 ± 2.9   25.5 ± 3.0
History of diabetes, (%)   20.8    22.2
History of hypertension, (%)  58.5    77.8
Family history of CAD‡, (%)  37.7    44.6
Diagnosis
 STEMI§, (%)   39.6    44.4
 Non-STEMI, (%)   9.4    16.7
 Unstable angina, (%)  50.9    38.9
Laboratory
 Leucocyte count   9 .6 ± 3.4    9.5 ± 2.7
 B lood sugar, mg/dL  147.4 ± 63.0   128.9 ± 49.5
 T otal cholesterol, mg/dL  185.6 ± 46.9   187.5 ± 46.0
 LDL-cholesterol, mg/dL  126.9 ± 32.9   127.1 ± 43.0
 HDL-cholesterol, mg/dL  40.4 ± 9.7   36.8 ± 12.5
 T riglycerides, mg/dL  130.2 ± 65.8   133.6 ± 71.2
Treatment
 A spirin, (%)   98.1    94.4
 C lopidogrel, (%)   98.1    100.0
 Beta-blockers, (%)  60.4    61.1
 S tatins, (%)   100.0    100.0
 Anti-coagulants, (%)  100.0    100.0
 F ibrinolytics, (%)   13.2    16.7
 PCI||, (%)   5.7    5 .6  
* Low neopterin group < 14.72 nmol/L
† High neopterin group ≥ 14.72 mmol/L
‡ CAD = Coronary artery disease
§ STEMI = ST-elevation myocardial infarction
|| PCI = Percutaneous coronary intervention
Table 2. Type and proportions of CV events throughout the study      
in cohort of 71 ACS subjects
  Type of CV* events    Percentage (%)
Cardiovascular death       19.0
Recurrent myocardial infarction      9 .5
Recurrent myocardial ischemia      71.5
Stroke         0 .0
* CV = Cardiovascular
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Figure 1. Estimates of CV events across quartiles of baseline neopterin. The log-rank test compared the difference in CV events across 
increasing quartiles of neopterin (P = 0.047).
Table 3. Relative risk of CV events Among Subjects With Highest Neopterin     
quartile group and Other Predictors in Multivariable Adjustment 
 Predictors   RR*  95% CI†  P value
Age     1 .52  0 .60 – 3.84  0.37
Hypertension    1 .04  0 .38 – 2.83  0.94
Diabetes mellitus    1 .17  0 .41 – 3.28  0.76
Family history of CAD‡   0 .96  0 .36 – 2.54  0.95
Neopterin (4th Q vs. 1st Q§)  5.84  1.19 – 28.47  0.029
* RR = relative risk
† CI = conﬁdence interval 
‡ CAD = coronary artery disease
§ Q = quartile
This model adjusts for age, history of hypertension, diabetes mellitus and family history of CAD.
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The results of our study show that neopterin, a 
biomarker of activated macrophage, predicts adverse 
CV events during follow-up in subjects with ACS. To 
our knowledge, this is the ﬁrst clinical study performed 
in non-Caucasian population. After multivariable 
adjustment, patients in the highest quartile of serum 
neopterin concentrations had a 5 to 6-fold higher risk 
of developing adverse CV events than those in the 
lowest quartile. This association was present across a 
range of baseline characteristics and was statistically 
signiﬁcant after adjustment for conventional risk 
factors, biochemical and treatment allocation. Thus, 
serum neopterin may be useful as prognostic factor 
in patients with ACS. Our results conﬁrm and are 
consistent with previous ﬁndings from other study 
(12). This ﬁnding strongly suggests that increased 
activation of monocyte-macrophage system is a 
speciﬁc feature of high-risk ACS patient for CV death 
or recurrent acute coronary events.
Increased circulating T-lymphocyte activity, 
which leads to elevated production of interferon- , is 
implicated in the pathogenesis of ACS (17). CD4+ and 
CD8+ T-lymphocyte are proven to activate in patients 
with unstable angina and their activation state lasts 6 
to 8 weeks (18). They are largely of the T-helper (Th1) 
subtype, which secretes interleukin-2, tumor necrosis 
factor-  and interferon- , which causes macrophage 
activation, vascular activation, and inﬂammation (19). 
Production of neopterin by activated macrophage 
is mainly in response to stimulation by interferon-  
released by activated T-lymphocyte (19). Consequently, 
serum neopterin concentrations may represent the 
whole state of cell-mediated immunity within subjects 
with ACS. 
Serum neopterin as a biomarker of macrophage 
activation is signiﬁcantly increased in patients with 
AMI and unstable angina shortly after the onset of 
symptoms (after period of 72 hours) (20). Further, in 
regard to reliability of neopterin measurement, there is 
no signiﬁcant ‘sex dependence’ and values for subjects 
younger or older than 75 years were signiﬁcantly 
higher (21). This is the reason why we measured 
neopterin at 3rd hospitalization day, and the age-range 
of our sample was only limited from 30 to 74 years 
old. The present study may be considered to be valid 
based on several reasons: a) the recruited samples 
represent the population of ACS in Bali, with spectrum 
Discussion
ranged from unstable angina, NSTEMI and STEMI 
(22), b) the follow-up was long enough for assessing 
the clinical outcomes, with 213 median-days, c) the 
clinical outcomes were assessed with no knowledge 
of the result of studied variable (neopterin), d) there 
were adjustments performed in order to prove the true 
association between neopterin concentration and the 
risk of CV events.           
Recently, the prognostic value of elevated serum 
neopterin was studied in chronic stable angina pectoris 
(8). The cut-off point of neopterin to predict future 
adverse cardiac events in that study is lower than 
ours (7 nmol/L vs. 14.72 nmol/L). This lower cut-off 
point is basically due to different studied population, 
namely chronic stable angina which represents less 
inﬂammatoric state than ACS population. Large-scale 
data on neopterin cut-off points in ACS actually are 
lacking. Ray et.al. (2007) determined neopterin cut-
off point of ≥ 12.11 nmol/L in ACS population (12). 
Although the population is about the same as ours, 
but the cut-off point is even lower. Probably, our 
population is more inﬂammatoric, as represented by 
higher proportion of CV risk factors found (such as, 
diabetes mellitus, hypertension and LDL-cholesterol 
concentration). Percentage of STEMI in our study is 
more than Ray’s study. Another reported study on 210 
patients with NSTEMI from the FLORIDA (Fluvastatin 
On Risk Diminishing after Acute myocardial 
infarction) trial used a threshold of 9.7 nmol/L, which 
represented the lower limit of the upper tertile. But it 
showed similar results to the present ﬁnding over a 
1-year period of follow-up (23).   
LIMITATION OF THE STUDY
The study limitation is the relatively small size 
of recruited subjects, though the study power is 
statistically modest. The neopterin cut-off point of 
≥ 14.72 nmol/L used to deﬁne a higher level in the 
present study was not speciﬁed a priori and was based 
on the available neopterin data post hoc. Nevertheless, 
validation of this cut-off point in ACS population needs 
to be clariﬁed in large prospective study. However, 
even with the relatively small sample size, elevated 
serum neopterin concentration was considered as a 
useful prognostic factor.         
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CONCLUSION
Our study shows that elevated serum neopterin 
concentrations are associated with development of 
adverse CV events in ACS patients. This association 
is independent of the severity of ACS and baseline CV 
risk factors, as well as treatment allocation.  
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